The US Centers for Disease and Prevention (CDC) no longer recommends that all US newborns receive the hepatitis B vaccine, ...
GSK's Exdensur (depemokimab) is now the first FDA-approved, twice-yearly add-on maintenance therapy for severe eosinophilic asthma.
Targeted patient recruitment can increase the likelihood of trial success and help cultivate use of precision medicine.
Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement ...
INCOG BioPharma Services has announced an injectable drug manufacturing expansion at its Fishers facility in Indiana, US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback